SCHEMBL628103

SCHEMBL628103

CCN(C)c1nc(-n2cccn2)nc2ccc(N3CCCCC3)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 10/20 0.55
ADORA2A P29274 4/20 0.40
CHRNA7 P36544 1/20 0.38
CHRNA10 Q9GZZ6 1/20 0.38
CHRNA9 Q9UGM1 1/20 0.38
RORC P51449 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626904 0.92 EGLN1 (0.66) EGLN1ADORA2ACHRNA7CHRNA10CHRNA9
SCHEMBL627216 0.90 EGLN1 (0.51) EGLN1ADORA2AHRH3LMNAHTT
SCHEMBL626312 0.81 ADORA2A (0.54) EGLN1ADORA2AKDM4EALDH1A1HPGD
SCHEMBL622352 0.81 EGLN1 (0.84) EGLN1
SCHEMBL627068 0.79 EGLN1 (0.67) EGLN1ADORA2AMAPTHTT
SCHEMBL14992354 0.78 EGLN1 (0.65) EGLN1ADORA2AMAPTHTT
SCHEMBL14992623 0.78 EGLN1 (0.69) EGLN1
SCHEMBL14992042 0.78 EGLN1 (0.67) EGLN1ADORA2ARORCKDM4ECYP3A4
SCHEMBL16626234 0.76 KDM4E (0.55) EGLN1ADORA2AKDM4EALDH1A1LMNA
SCHEMBL14992599 0.75 EGLN1 (0.54) EGLN1ADORA2AALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-04-02 US disclosed
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-31 US disclosed
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9573940-B2 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-16 US disclosed
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARAMCEUTICA NV (BE) 2014-10-16 US disclosed
US-8796263-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-08-05 US disclosed
EP-2603502-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-06-19 EP disclosed
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-06-06 US disclosed
WO-2012021830-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885CHRNA7 4870/4885
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885CHRNA7 4870/4885
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885CHRNA7 4845/4885
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3619/4885CHRNA7 4869/4885
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885CHRNA7 4870/4885
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885CHRNA7 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.